B. Riley Securities Reiterates Buy Rating on UNCY, Sets $22 Target
B. Riley Securities reaffirmed its buy rating on UNCY with a $22 price target, a 379.30% upside from the current price.
Key Points
- B. Riley Securities reiterated its buy rating on UNCY, setting a $22 price target on June 30, 2026.
- UNCY shares traded at $4.59 on Tuesday, suggesting significant potential upside.
- Other analysts like HC Wainwright & Co. and Benchmark also maintain buy ratings with targets of $15 and $18 respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 30, 2026, B. Riley Securities reaffirmed its buy rating on UNCY, setting a price target of $22. This rating was maintained by analyst Mayank Mamtani, who sees potential for the stock, which traded at $4.59 on Tuesday.
B. Riley Securities vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in UNCY
VIVO CAPITAL, LLC held steady with 1,789,916 shares valued at about $11.8 million. Meanwhile, MILLENNIUM MANAGEMENT LLC increased its stake by 384,505 shares, bringing its total to 1,399,348 shares worth approximately $9.2 million, marking a 37.9% increase. OCTAGON CAPITAL ADVISORS LP and NANTAHALA CAPITAL MANAGEMENT, LLC maintained their positions with 1,000,000 and 939,202 shares respectively. VANGUARD CAPITAL MANAGEMENT LLC opened a new position with 811,430 shares valued at about $5.3 million.
Unicycive Therapeutics, Inc. Stock Down 12.8%
Shares of UNCY traded near $4.59 on Tuesday. The stock's recent activity suggests investor interest, particularly following the analyst reiteration from B. Riley Securities.
$UNCY price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Insider Buying and Selling at Unicycive Therapeutics, Inc.
On May 14, 2026, several insiders made notable purchases. Pramod Gupta, EVP of Pharmaceuticals and BD, bought 169,500 shares. Similarly, Douglas Jermasek, EVP of Corporate Strategy, and John Townsend, CFO, each acquired 169,500 shares. CEO Shalabh Gupta made a larger purchase of 762,200 shares. These transactions were not conducted under a Rule 10b5-1 plan.
Analysts Set New Price Targets
On June 30, 2026, HC Wainwright & Co. maintained its buy rating with a $15 target. B. Riley Securities also reaffirmed its buy rating, setting a $22 target. Earlier in the month, Benchmark maintained a buy rating with an $18 target on June 2. Overall, the consensus remains positive, with multiple firms maintaining buy ratings.
Bottom Line
B. Riley Securities' reiteration of a buy rating and $22 target for UNCY highlights confidence in the stock's potential. While the current price of $4.59 suggests room for growth, investors should remember that these are backward-looking analyses. As always, it's important to consider the broader market context and individual investment goals.
Get Unicycive Therapeutics, Inc. alerts
New 13F filings, insider trades, and analyst moves on $UNCY, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.